Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 15/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720234 | 0.87 | TRPA1 (0.36) | ADORA2BADORA1FLT3SYKAURKB | |
| SCHEMBL1065318 | 0.84 | ADORA2B (0.58) | ADORA2BADORA1ADORA2AADORA3 | |
| SCHEMBL1065068 | 0.77 | ADORA2B (0.60) | ADORA2BADORA1ADORA2AADORA3 | |
| SCHEMBL1081716 | 0.75 | ADORA2B (0.58) | ADORA2BADORA1ADORA2AADORA3 | |
| SCHEMBL1065416 | 0.75 | ADORA2B (0.56) | ADORA2BADORA1ADORA2AADORA3 | |
| SCHEMBL30891840 | 0.75 | ADORA2B (0.49) | ADORA2BADORA1ADORA2AADORA3 | |
| SCHEMBL2686448 | 0.75 | ADORA2B (0.49) | ADORA2BADORA1ADORA2AADORA3 | |
| SCHEMBL30891847 | 0.75 | ADORA2B (0.74) | ADORA2BADORA1ADORA2A | |
| SCHEMBL2685092 | 0.75 | ADORA2B (0.74) | ADORA2BADORA1ADORA2A | |
| SCHEMBL2684217 | 0.74 | ADORA2B (0.38) | ADORA2BADORA1FLT3SYKAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307402-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER | IMPETIS BIOSCIENCES LTD. (IN) | 2024-09-19 | — | — | US | claimed |
| CN-118001282-A | Pharmaceutical composition for cancer treatment | 因佩蒂斯生物科学有限公司 | 2024-05-10 | — | — | CN | claimed |
| EP-3727391-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER | Impetis Biosciences Ltd. (IN) | 2020-10-28 | — | — | EP | claimed |
| CN-111801099-A | Pharmaceutical composition for cancer treatment | 因佩蒂斯生物科学有限公司 | 2020-10-20 | — | — | CN | claimed |
| US-20200316077-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER | IMPETIS BIOSCIENCES LTD. (IN) | 2020-10-08 | — | — | US | claimed |
| US-20150087643-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2015-03-26 | — | — | US | claimed |
| EP-2405917-B1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS | ADVINUS THERAPEUTICS PRIVATE LTD (IN) | 2014-04-23 | — | — | EP | claimed |
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-05-10 | — | — | US | claimed |
| US-20240307402-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER | IMPETIS BIOSCIENCES LTD. (IN) | 2024-09-19 | — | — | US | disclosed |
| CN-118001282-A | Pharmaceutical composition for cancer treatment | 因佩蒂斯生物科学有限公司 | 2024-05-10 | — | — | CN | disclosed |
| EP-3727391-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER | Impetis Biosciences Ltd. (IN) | 2020-10-28 | — | — | EP | disclosed |
| CN-111801099-A | Pharmaceutical composition for cancer treatment | 因佩蒂斯生物科学有限公司 | 2020-10-20 | — | — | CN | disclosed |
| US-9284316-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2016-03-15 | — | — | US | disclosed |
| US-20150087643-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
| US-8859566-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2014-10-14 | — | — | US | disclosed |
| EP-2405917-B1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS | ADVINUS THERAPEUTICS PRIVATE LTD (IN) | 2014-04-23 | — | — | EP | disclosed |
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200316077-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885ADORA1 8/4885FLT3 1192/4885 |
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADORA2A, ADORA1, ADORA3 | ADORA2B 4/4885ADORA1 2/4885FLT3 1365/4885 |
| US-20150087643-A1 | Substituted Fused Pyrimidine Compounds | ADORA2A, ADORA1, ADORA3 | ADORA2B 4/4885ADORA1 2/4885FLT3 1382/4885 |
| US-20240307402-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885ADORA1 8/4885FLT3 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.